Finally, the ability to perform large-scale genetic screens together with the availability of RNA interference for all genes annotated in the fly genome, make it possible to identify novel modifiers of Aβ42 and Tau (Jeon et al., 2020) that not only provide insight into the molecular and cellular pathways implicated in AD but also potential novel therapeutic targets for this devastating disease. The gene discussed is MAPT; the disease is Alzheimer disease.